Tumor markers after radiofrequency ablation therapy for hepatocellular carcinoma |
| |
| Authors: | Ogawa Chikara Kudo Masatoshi Minami Yasunori Chung Hobyung Kawasaki Toshihiko |
| |
| Affiliation: | Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kinki University School of Medicine, Osaka-Sayama, Japan. |
| |
| Abstract: | BACKGROUND/AIMS: The aim of this study was to evaluate the clinical value of measurement of the AFP-L3 fraction before and after radiofrequency ablation (RFA) therapy for HCC, compared with the measurement of total AFP and des-gamma-carboxy prothrombin (DCP). METHODOLOGY: One hundred and twenty-four patients with HCCs were evaluated for their complete response with a 5-mm-thick safety margin around the tumor. Three tumor markers (AFP, DCP, AFP-L3) were measured after RFA therapy, and their clinical significance was studied. RESULTS: Multivariate analysis revealed that of the three tumor makers only AFP-L3 showed significant differences in the survival and disease-free rates. CONCLUSIONS: AFP-L3 is the most reliable tumor marker for estimating overall survival and disease-free survival in patients with HCC effectively treated by RFA in contrast to AFP and DCP. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
